Press releases

Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the FARAPULSE™ Pulsed Field Ablation System* Results from global trial of the POLARx™...

Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023. Mike Mahoney, chairman and chief executive officer,...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational1 basis...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2023 on Wednesday, April 26,...

Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference on Wednesday, March 1, 2023. Dan Brennan, executive vice president...

New technology designed to help inform real-time clinical decisions during kidney stone procedures MARLBOROUGH, Mass., Feb. 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and...

Boston Scientific Corporation (NYSE: BSX) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 in San Francisco, California. Mike Mahoney, chairman...

Boston Scientific Corporation (NYSE: BSX) and Acotec Scientific Holdings Limited ("Acotec" and 6669.HK) announced today that Boston Scientific will make a partial offer to acquire a majority...

Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures MARLBOROUGH, Mass., Nov. 29, 2022 /PRNewswire/ -- Boston Scientific Corporation...

Boston Scientific Corporation (NYSE:BSX) has announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of the ACURATE neo2TM Aortic...

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On November 15, 2022, Dan Brennan, executive vice president and chief financial officer, and Lauren...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.170 billion during the third quarter of 2022, growing 8.1 percent on a reported basis, 13.7 percent on an operational1 basis and...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2022 on Wednesday, October...

Marlborough, Mass., September 19, 2022 — Boston Scientific Corporation (NYSE: BSX) announces the appointment of Kathryn Unger as vice president, Environmental, Social and Governance (ESG)....

Results from largest randomized TAVR trial to date presented at TCT 2022 MARLBOROUGH, Mass., Sept. 17, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has announced results from the...

WATCHMAN FLX now the only LAAC technology in the United States that allows for either DAPT or OAC immediately following implantation MARLBOROUGH, Mass., Sept. 6, 2022 /PRNewswire/ -- Boston...

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor events. On Wednesday, September 7, 2022, Mike Mahoney, chairman and chief executive officer, and Lauren Tengler,...

Company to add novel technology cleared for use in peripheral vasculature to interventional oncology and embolization portfolio MARLBOROUGH, Mass., Aug. 15, 2022 /PRNewswire/ -- Boston Scientific...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.244 billion during the second quarter of 2022, growing 5.4 percent on a reported basis, 9.6 percent on an operational1 basis and...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2022 on Wednesday, July 27,...

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Synergy Innovation Co., Ltd, to purchase its majority stake (approximately 64...

Boston Scientific Corporation (NYSE: BSX) will participate in Bank of America's Global Healthcare Conference on Thursday, May 12. Dan Brennan, executive vice president and chief financial officer, and

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the EMBOLD™ Fibered Detachable Coil,...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis...

Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for its latest image guided...

Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2022, on Wednesday, April 27,...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the pricing terms of the previously announced upsized cash tender offer (the "Tender Offer") for $2,852,561,000 in...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $2.5 billion aggregate...

Boston Scientific Corporation (NYSE: BSX) (the "Company") today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has completed a public offering of...

Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has priced a public offering of...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the commencement of a cash tender offer (the "Tender Offer") for up to $2.5 billion aggregate principal amount (the...

Boston Scientific Corporation (NYSE: BSX) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device....

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as...

Boston Scientific Corporation (NYSE: BSX) will participate in SVB Leerink's 11th Annual Global Healthcare Conference on Thursday, February 17, 2022. Dan Brennan, executive vice president and chief...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.127 billion during the fourth quarter of 2021, growing 15.4 percent on a reported basis, 16.9 percent on an operational1 basis...

Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at the 25th North American Neuromodulation Society (NANS) annual meeting, in Orlando, Florida, on...

Boston Scientific Corporation (NYSE: BSX) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022. Mike Mahoney, chairman and chief executive officer,...

Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM System...

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On November 15, 2021, Dan Brennan, executive vice president and chief financial officer, and Lauren...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational1 basis and...

October 20, 2021 – Boston Scientific Corporation announces that it reached a settlement with Micro-Tech Endoscopy resolving claims of patent infringement by Boston Scientific against Micro-Tech...

Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at...

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to...

Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular...

Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2021 on Wednesday, October...

Today, Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform. The innovative non-console and lytic-free...

Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment) successfully met both primary endpoints,...

Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 22, 2021, from 8:30...